Sokal-Dembowska Aneta, Jarmakiewicz-Czaja Sara, Helma Kacper, Filip Rafał
Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.
Department of Internal Medicine, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-959 Rzeszow, Poland.
Int J Mol Sci. 2025 May 15;26(10):4750. doi: 10.3390/ijms26104750.
Deregulation of microRNAs (miRNAs) has been implicated in the development of inflammatory bowel disease (IBD). Specific miRNAs are differentially expressed in patients with IBD compared to healthy individuals. Regulation of their expression can modulate the inflammatory response, the composition of the intestinal microbiota, and intestinal barrier function. miRNAs can regulate the immune and inflammatory response via multiple mechanisms, from Th1/Th17 regulation and ferroptosis to modulation of NLRP3 (NOD-like receptor family, pyrin domain-containing 3) and control of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. The use of miRNAs as biomarkers and therapeutic targets may help monitor IBD treatment and support the development of new, more individualized therapies that minimize common side effects.
微小RNA（miRNA）失调与炎症性肠病（IBD）的发生发展有关。与健康个体相比，IBD患者体内特定的miRNA表达存在差异。其表达的调控可调节炎症反应、肠道微生物群组成和肠道屏障功能。miRNA可通过多种机制调节免疫和炎症反应，从Th1/Th17调节、铁死亡到NLRP3（含pyrin结构域的NOD样受体家族3）的调节以及NF-κB（活化B细胞核因子κ轻链增强子）信号通路的控制。将miRNA用作生物标志物和治疗靶点可能有助于监测IBD的治疗，并支持开发新的、更具个性化的疗法，以尽量减少常见的副作用。
